Sugi Predict

Sugi Predict / Targets / ITGAV

ITGAV

Integrin alpha-V · P06756 · ITGAV on Sugi Atlas →

94,083 patent compounds predicted against ITGAV, 58,160 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL244300 SCHEMBL244300 1.00 20/20
SCHEMBL244675 SCHEMBL244675 1.00 20/20
SCHEMBL245523 SCHEMBL245523 1.00 20/20
SCHEMBL328727 SCHEMBL328727 1.00 20/20
SCHEMBL244091 SCHEMBL244091 0.91 20/20
SCHEMBL381992 SCHEMBL381992 0.86 20/20
SCHEMBL343164 SCHEMBL343164 0.76 20/20
SCHEMBL330242 SCHEMBL330242 0.74 20/20
SCHEMBL336839 SCHEMBL336839 0.73 20/20
SCHEMBL329866 SCHEMBL329866 0.73 20/20
SCHEMBL382505 SCHEMBL382505 0.70 20/20
SCHEMBL328153 SCHEMBL328153 0.69 20/20
SCHEMBL275079 SCHEMBL275079 0.69 20/20
SCHEMBL244092 SCHEMBL244092 0.68 20/20
SCHEMBL327994 SCHEMBL327994 0.68 20/20
SCHEMBL274666 SCHEMBL274666 0.67 20/20
SCHEMBL276613 SCHEMBL276613 0.67 20/20
SCHEMBL328135 SCHEMBL328135 0.67 20/20
SCHEMBL344876 SCHEMBL344876 0.67 20/20
SCHEMBL336429 SCHEMBL336429 0.66 20/20

Clinical trials — most relevant to ITGAV by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. PHASE4COMPLETED
68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Myocardial Angiogenesis PHASE2COMPLETED
Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer PHASE1/PHASE2COMPLETED
Imaging Studies and the Development of Multiple Myeloma PHASE2WITHDRAWN
68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Angiogenesis in Ischemic Heart Disease PHASE2UNKNOWN
Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors PHASE1COMPLETED
A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I PHASE1WITHDRAWN
A Study to Evaluate Adverse Events and How the Drug Moves Through the Body From Subcutaneous (SC) and Intravenous (IV) Doses of ABBV-382 in Healthy Adult Chinese Volunteers PHASE1COMPLETED
68Ga-BNOTA-PRGD2 PET/CT in Patients With Rheumatoid Arthritis EARLY_PHASE1UNKNOWN
68Ga-NOTA-PRGD2 PET/CT in Patients With Lung Injury and Pulmonary Fibrosis EARLY_PHASE1UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma EARLY_PHASE1UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Stroke EARLY_PHASE1UNKNOWN
An Open-label, Single-arm, Single-center Study to Evaluate the Diagnostic Efficacy of a Novel PET Probe, 68Ga-SFB6-ZN01, in Patients With Malignant Tumors EARLY_PHASE1NOT_YET_RECRUITING
68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Myocardial Infarction EARLY_PHASE1UNKNOWN
99mTc-3PRGD2 SPECT/CT in Rheumatoid Arthritis Patients EARLY_PHASE1COMPLETED
99mTc-3PRGD2 SPECT/CT in Esophagus Cancer Patients EARLY_PHASE1COMPLETED
99mTc-3PRGD2 SPECT/CT in Lung Cancer Patients EARLY_PHASE1UNKNOWN
177Lu-AB-3PRGD2 in Patients With Integrin αVβ3 Positive Tumors EARLY_PHASE1RECRUITING
177Lu-TATE-RGD in Patients With SSTR2 and Integrin αVβ3 Positive Tumors EARLY_PHASE1RECRUITING
68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer Patients EARLY_PHASE1UNKNOWN
Clinical Study of 18F-FAPI-RGD in Ovarian Cancer nanCOMPLETED
Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS) nanCOMPLETED
Angiogenesis and Fibrosis in Aortic Stenosis nanCOMPLETED
Integrin αvβ6-targeted PET in Malignant Tumors nanRECRUITING
Clinical Study of 18F-FAPI-RGD in Breast Tumors nanCOMPLETED
Hypolipemic Treatment in Acute Coronary Syndrome (ACS): Antithrombotic Effects nanUNKNOWN
IMaging Pilot Study of the αvβ6 Integrin Radiotracer [18F]-A20FMDV2 in PAtients With Solid Cancer Types nanCOMPLETED
Angiogenesis and Fibrosis in Myocardial Infarction nanCOMPLETED
The Role of Platelet Surface α2β1 Integrin Expression as a Risk Factor in Thrombotic and/or Bleeding Complications nanCOMPLETED
99mTc-3PRGD2 SPECT/CT in Breast Cancer Patients nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ITGAV binder may also engage these)

ProteinNameSimilarity
P80746 — 1.000 P80746 →
P43406 — 1.000 P43406 →
P26008 — 1.000 P26008 →
Q91687 — 0.998 Q91687 →
Q06274 — 0.994 Q06274 →
Q61739 — 0.994 Q61739 →
P26007 — 0.991 P26007 →
P61622 — 0.991 P61622 →
ITGA6 Integrin alpha-6 0.990 landscape →
Q9UKX5 — 0.988 Q9UKX5 →
A2ARA8 — 0.987 A2ARA8 →
Q62470 — 0.987 Q62470 →
ITGA8 Integrin alpha-8 [Cleaved into: Integrin alph 0.986 landscape →
F1MMS9 — 0.984 F1MMS9 →
Q00651 — 0.984 Q00651 →
Q61738 — 0.982 Q61738 →
P26006 — 0.982 P26006 →
P11688 — 0.981 P11688 →
ITGB4 Integrin beta-4 0.981 landscape →
O54800 — 0.981 O54800 →
A7MB70 — 0.981 A7MB70 →
Q6AYF4 — 0.981 Q6AYF4 →
Q90763 — 0.980 Q90763 →
A2A863 — 0.980 A2A863 →
Q13683 — 0.980 Q13683 →
Q62469 — 0.980 Q62469 →
P17852 — 0.980 P17852 →
Q63258 — 0.980 Q63258 →
P97278 — 0.980 P97278 →
P18563 — 0.979 P18563 →